1. Systematic review on the use of biosimilars of trastuzumab in HER2+ breast cancer;Triantafyllidi;Biomedicines,2022
2. Breast cancer: Epidemiology, risk factors, classification, prognostic markers, and current treatment strategie - an updated review;Łukasiewicz;Cancers,2021
3. Howard J. Women should start screening for breast cancer at age 40 instead of 50, health task force says in draft recommendation. CNN Health: https://www.cnn.com/2023/05/09/health/breast-cancer-screening-age-40-uspstf/index.html [Accessed 9 May 2013].
4. Breast Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology;Gradishar;J. Natl. Compr. Canc. Netw.,2022
5. European Medicines Agency: Similar Biological Medicinal Products CHMP/437/04 Rev. 1. 23 October 2014 CHMP/437/04 Rev 1 Committee for Medicinal Products for Human Use (CHMP). Available online: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2014/10/WC500176768.pdf[accessed on 12 December 2022].